These studies confirmed the high specificity of the T2–FLAIR mismatch sign for noninvasive detection of IDH-mutant 1p/19q-noncodeleted gliomas; however, sensitivity is low and applicability is limited to low-grade gliomas and glioblastomas. Here, IDH1 is linked to central nervous system cancer.